Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of QY201 tablets in moderate-to-severe prurigo nodularis
CTR20254407Phase 2Active
- Sponsor
- Origin Biosciences
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in prurigo nodularis (PN) comparing QY201 with Placebo (2 arms). Primary endpoint: Proportion of participants achieving at least a 4-point reduction from baseline in weekly average WI-NRS at Week 16. Started Dec 2025; status: active.
02
Drugs
qy201
03
Conditions
prurigo nodularis (PN)
Beyond the preview
Go deeper on CTR20254407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254407.